The Food and Drug Administration is investigating serious adverse events involving Limbrel, a capsule being marketed as a medical food to manage the metabolic processes associated with osteoarthritis. Health care providers who know their patients are taking the product should advise them to stop taking it immediately, FDA said. While a range of adverse events have been reported, two serious and potentially life-threatening medical conditions are among them: drug-induced liver injury and hypersensitivity pneumonitis. For more information, see the FDA safety alert.

Related News Articles

Headline
As more female physicians enter the workforce and face challenges that can lead to burnout, the AHA has joined with five medical organizations to bring…
Insights and Analysis
Also in this roundup of nursing news: a nurse perseveres through extreme snow to tend to a home-bound patient, and executive moves in the field.
Insights and Analysis
Also in this roundup of nurse-related news: a school nurse saves a student’s life, and executive moves in the field.
Headline
The Schwartz Center for Compassionate Healthcare will hold its 2019 Compassion in Action Healthcare Conference Sept. 8-10 in Boston.
Insights and Analysis
Also in this weekly roundup of nursing news: video of nurse singing to patient goes viral, and executive moves in the field.
Insights and Analysis
Also in this weekly roundup of nurse-related news: remembering America’s first black nurse, and executive moves in the field.